PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1485739
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1485739
Live Biotherapeutics Products & Microbe CDMO Market size was valued at USD 20.34 million in 2023, expanding at a CAGR of 40.5% from 2024 to 2032.
The Live Biotherapeutics Products & Microbe CDMO market involves developing, manufacturing, and commercializing therapeutic products based on live microbes for medical applications. The increasing demand for microbiome-based therapies is driven by awareness of the microbiome's role in health, advancements in microbial engineering enabling customized therapeutics, and the rising prevalence of chronic diseases facilitating market entry. However, challenges such as the complexity of microbiome research, manufacturing scalability issues, safety concerns, and limited market understanding pose restraints on market growth. Opportunities lie in expanding therapeutic applications beyond gastrointestinal disorders, increased R&D investment in microbiome therapeutics, and personalized medicine approaches enhancing targeted treatment strategies in healthcare.
Live Biotherapeutics Products & Microbe CDMO Market- Market Dynamics
Advancing R&D Initiatives in Next-Generation Live Biotherapeutics and Microbiome Contract Manufacturing
Advancing R&D initiatives in next-generation live biotherapeutics and microbiome contract manufacturing are reshaping therapeutic development. For instance, the National Institutes of Health (NIH) has allocated significant funding towards microbiome research, highlighting its importance in healthcare innovation. Additionally, leading biopharmaceutical companies like Seres Therapeutics and Vedanta Biosciences are pioneering novel live biotherapeutic candidates, emphasizing the potential of microbiome-based therapies. Collaborations between academic institutions and CDMOs, such as the partnership between the University of California, San Diego, and SGI-DNA for synthetic biology solutions, showcase the growing integration of advanced technologies in microbiome-focused manufacturing. These efforts underscore a transformative shift towards personalized, microbiome-targeted therapeutics with broad clinical implications.
Live Biotherapeutics Products & Microbe CDMO Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 40.5% over the forecast period (2024-2032)
Based on Service Type segmentation, Manufacturing Services was predicted to show maximum market share in the year 2023
Based on the Scale of Operation segmentation, Clinical Scale Operations was the leading type in 2023
Based on region, North America was the leading revenue generator in 2023
The Global Live Biotherapeutics Products & Microbe CDMO Market is segmented based on Service Type, Scale of Operation, Application, and Region.
The market is divided into two categories based on Service Type: Development Services and Manufacturing Services. Consumers typically prioritize Manufacturing Services over Development Services due to the critical need for specialized manufacturing capabilities in producing live biotherapeutic products. Efficient and scalable manufacturing processes are essential for the commercialization and market supply of microbiome-based therapies.
The market is divided into three categories based on Scale of Operation: Preclinical Scale Operations, Clinical Scale Operations, and Commercial Scale Operations. Operations typically prioritize Clinical Scale Operations followed by Commercial Scale Operations and then Preclinical Scale Operations. Clinical scale operations are critical for advancing product development towards regulatory approval and commercialization, while commercial scale operations ensure market supply and scalability of live biotherapeutics.
Live Biotherapeutics Products & Microbe CDMO Market- Geographical Insights
North America holds a prominent position, driven by robust R&D activities and investments in microbiome-based therapies by leading pharmaceutical and biotechnology companies. Europe follows closely, with established regulatory frameworks supporting innovation in live biotherapeutics and CDMO services. Asia Pacific showcases rapid growth potential, attributed to increasing healthcare expenditure, rising adoption of advanced biotechnology, and growing partnerships between local and international players. Emerging economies in this region, particularly in countries like China and India, are witnessing a surge in microbiome-focused research and development, contributing to market expansion.
Key players like Lonza Group, Charles River Laboratories, and Catalent are at the forefront, offering comprehensive CDMO services for live biotherapeutics development and manufacturing. Seres Therapeutics and Vedanta Biosciences lead in live biotherapeutics products, focusing on microbiome-based therapies for various indications. Collaborations such as Bacteria and Seres Therapeutics for commercial manufacturing highlight the trend towards partnerships to enhance manufacturing capabilities and expand market reach. Emerging companies like SBT Instruments contribute innovative technologies, while established players invest in R&D to redefine the future of microbiome-focused therapies and contract manufacturing services. This competitive landscape underscores ongoing efforts to drive innovation and meet the growing demand for advanced live biotherapeutic products and CDMO solutions. Several companies are collaborating for the development and production of innovative live biotherapeutics. For instance, in October 2019, 4D Pharma plc announced a research collaboration and licensing agreement with MSD, Merck & Co., Inc., to discover and develop Live Biotherapeutic Products (LBPs) for vaccines.
In June 2023, Biose Industrie and SBT Instruments collaborated to integrate rapid viable cell counts into Biose's manufacturing, setting a new standard for microbe enumeration. This integration aims to expedite clinical trials and market approval for Biose's live biotherapeutic products.
In November 2021, Bacthera and Seres Therapeutics are collaborating to manufacture SER-109, Seres' lead product candidate for recurrent Clostridioides difficile infection (CDI). Bacthera is establishing a dedicated commercial manufacturing facility within its new Microbiome Center of Excellence located on Lonza's Ibex campus in Visp, Switzerland.
GLOBAL LIVE BIOTHERAPEUTICS PRODUCTS & MICROBE CDMO MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
4D Pharma PLC
Catalent, Inc.
Chr. Hansen Holding A/S
Evelo Biosciences, Inc.
Evonik Industries AG
Ferring Pharmaceuticals
Lonza Group AG
Microbiotica Ltd.
Pivot Bio
Rebiotix, Inc. (a Ferring Pharmaceuticals company)
Samsung Biologics
Second Genome, Inc.
Seres Therapeutics, Inc.
Synlogic, Inc.
Vedanta Biosciences, Inc.
Wacker Chemie AG
Others